Amplia Therapeutics Ownership
| INNMF Stock | USD 0.06 0.01 14.49% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Amplia |
Amplia Pink Sheet Ownership Analysis
About 22.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.6. Some equities with similar Price to Book (P/B) outperform the market in the long run. Amplia Therapeutics recorded a loss per share of 0.02. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 30th of April 2018. Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase inhibitors for oncology and chronic fibrosis in Australia. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia. Innate Immunotherapeuti is traded on OTC Exchange in the United States.The quote for Amplia Therapeutics Limited is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To learn more about Amplia Therapeutics Limited call BSc BSc at 61 2 8003 3650 or check out https://www.ampliatx.com.Currently Active Assets on Macroaxis
Other Information on Investing in Amplia Pink Sheet
Amplia Therapeutics financial ratios help investors to determine whether Amplia Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Amplia with respect to the benefits of owning Amplia Therapeutics security.